RBC Capital Reiterates Outperform Rating on United Therapeutics Corporation (UTHR)

Market Context

United Therapeutics Corporation operates in the Healthcare sector. The stock currently trades at $563.70 with a market capitalization of $21.8B. The stock has gained 85.8% over the past 52 weeks.

Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for United Therapeutics Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for United Therapeutics Corporation

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 07, 2026	RBC Capital	Outperform	N/A
May 07, 2026	RBC Capital	Outperform	N/A
May 07, 2026	Wells Fargo	Overweight	N/A
Apr 10, 2026	Morgan Stanley	Equal-Weight	N/A
Mar 31, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View UTHR Stock Page